Literature DB >> 4903319

Evaluation in man of fenclozic acid (I.C.I. 54,450: Myalex), a new anti-inflamatory agent. II. Clinical trial in patients with rheumatoid arthritis.

T M Chalmers, J H Kellgren, D S Platt.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1969        PMID： 4903319      PMCID： PMC1031293          DOI： 10.1136/ard.28.6.595

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  9 in total

1.  ADAPTATION OF BABSON'S METHOD FOR THE DETERMINATION OF SERUM GLUTAMIC OXALACETIC TRANSAMINASE IN THE CLINICAL LABORATORY.

Authors:  M FURUNO; A SHEENA
Journal:  Clin Chem       Date:  1965-01       Impact factor: 8.327

2.  Improvement of the uric acid determination by the carbonate method for serum and urine.

Authors:  F EICHHORN; S ZELMANOWSKI; E LEW; A RUTENBERG; B FANIAS
Journal:  J Clin Pathol       Date:  1961-07       Impact factor: 3.411

3.  DIAGNOSTIC criteria for rheumatoid arthritis: 1958 revision by a committee of the American Rheumatism Association.

Authors: 
Journal:  Ann Rheum Dis       Date:  1959-03       Impact factor: 19.103

4.  A rapid and precise method for the determination of urea.

Authors:  J K FAWCETT; J E SCOTT
Journal:  J Clin Pathol       Date:  1960-03       Impact factor: 3.411

5.  A method for testing analgesics in rheumatoid arthritis using a sequential procedure.

Authors:  J HAJNAL; J SHARP; A J POPERT
Journal:  Ann Rheum Dis       Date:  1959-09       Impact factor: 19.103

6.  The influence of probenecid, phenylbutazone and salicylates upon urate excretion in man.

Authors:  J H SIROTA
Journal:  Rheumatism       Date:  1957-10

7.  Clinical measurement of the anti-inflammatory effects of salicylates in rheumatoid arthritis.

Authors:  P L Boardman; F D Hart
Journal:  Br Med J       Date:  1967-11-04

8.  Pharmacokinetics of salicylate elimination in man.

Authors:  G Levy
Journal:  J Pharm Sci       Date:  1965-07       Impact factor: 3.534

9.  Evaluation in man of fenclozic acid (I.C.I. 54,450: Myalex), a new anti-inflammatory agent. I. Serum concentration studies in healthy individuals and in patients with rheumatoid arthritis.

Authors:  T M Chalmers; J E Pohl; D S Platt
Journal:  Ann Rheum Dis       Date:  1969-11       Impact factor: 19.103
  9 in total
  4 in total

1.  Improved hepatic physiology in hepatic cytochrome P450 reductase null (HRN™) mice dosed orally with fenclozic acid.

Authors:  James A Akingbasote; Alison J Foster; Huw B Jones; Rhiannon David; Nigel J Gooderham; Ian D Wilson; J Gerry Kenna
Journal:  Toxicol Res (Camb)       Date:  2016-11-09       Impact factor: 3.524

2.  Hepatic effects of fenzlozic acid.

Authors:  F D Hart; L S Bain; E C Huskisson; T R Littler; R T Taylor
Journal:  Ann Rheum Dis       Date:  1970-11       Impact factor: 19.103

3.  Acute liver effects, disposition and metabolic fate of [14C]-fenclozic acid following oral administration to normal and bile-cannulated male C57BL/6J mice.

Authors:  Kathryn Pickup; Scott Martin; Elizabeth A Partridge; Huw B Jones; Jonathan Wills; Tim Schulz-Utermoehl; Alan McCarthy; Alison Rodrigues; Chris Page; Kerry Ratcliffe; Sunil Sarda; Ian D Wilson
Journal:  Arch Toxicol       Date:  2016-11-28       Impact factor: 5.153

4.  The metabolic fate of fenclozic acid in chimeric mice with a humanized liver.

Authors:  Anja Ekdahl; Lars Weidolf; Matthew Baginski; Yoshio Morikawa; Richard A Thompson; Ian D Wilson
Journal:  Arch Toxicol       Date:  2018-08-09       Impact factor: 5.153
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.